"Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study"

LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles. Sign Up to like articles & get recommendations!

Safety and efficacy of nonacog alfa for the treatment of haemophilia B in children younger than 6 years of age in a routine clinical care setting: the EUREKIX registry study

European regulatory authorities request postmarketing safety and efficacy data for factor IX (FIX) products. Click to show full abstract

European regulatory authorities request postmarketing safety and efficacy data for factor IX (FIX) products.

Keywords: alfa treatment; efficacy nonacog; safety efficacy; safety; nonacog alfa

Journal Title: Haemophilia
Year Published: 2020

Link to full text (if available)

Share on Social Media: Sign Up to like & get
recommendations!
1

LAUSR

You are not signed in:

Sign Up!

Related content

More Information News Social Media Video Recommended